Reported Saturday, Eli Lilly's Olomorasib Presented Updated Data From The Phase 1/2 Study For KRAS G12C-Mutant Solid Tumors At ASCO 2024
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly presented updated data from its Phase 1/2 study for KRAS G12C-mutant solid tumors at ASCO 2024. The data showed promising monotherapy activity with olomorasib and a good tolerability profile in combination with pembrolizumab, making it suitable for first-line lung cancer development.
June 03, 2024 | 8:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's olomorasib has shown promising results in a Phase 1/2 study for KRAS G12C-mutant solid tumors, including non-small cell lung cancer. The drug also demonstrated a good tolerability profile in combination with pembrolizumab, making it suitable for first-line lung cancer development.
The positive data from the Phase 1/2 study for olomorasib, especially its efficacy and tolerability, is likely to boost investor confidence in Eli Lilly's oncology pipeline. This could lead to a short-term increase in LLY's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100